PL3066126T3 - Leczenie skojarzone z zastosowaniem niefukozylowanego przeciwciała anty-CD20 i inhibitora BTK - Google Patents
Leczenie skojarzone z zastosowaniem niefukozylowanego przeciwciała anty-CD20 i inhibitora BTKInfo
- Publication number
- PL3066126T3 PL3066126T3 PL14796468T PL14796468T PL3066126T3 PL 3066126 T3 PL3066126 T3 PL 3066126T3 PL 14796468 T PL14796468 T PL 14796468T PL 14796468 T PL14796468 T PL 14796468T PL 3066126 T3 PL3066126 T3 PL 3066126T3
- Authority
- PL
- Poland
- Prior art keywords
- antibody
- combination therapy
- btk inhibitor
- fucosylated anti
- fucosylated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13192006 | 2013-11-07 | ||
| PCT/EP2014/073640 WO2015067586A2 (en) | 2013-11-07 | 2014-11-04 | Combination therapy of an anti cd20 antibody with a btk inhibitor |
| EP14796468.8A EP3066126B1 (en) | 2013-11-07 | 2014-11-04 | Combination therapy of an anti cd20 antibody with a btk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3066126T3 true PL3066126T3 (pl) | 2019-08-30 |
Family
ID=49552219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14796468T PL3066126T3 (pl) | 2013-11-07 | 2014-11-04 | Leczenie skojarzone z zastosowaniem niefukozylowanego przeciwciała anty-CD20 i inhibitora BTK |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20150125446A1 (pl) |
| EP (1) | EP3066126B1 (pl) |
| JP (1) | JP6478989B2 (pl) |
| KR (1) | KR101874215B1 (pl) |
| CN (3) | CN114632158A (pl) |
| AR (1) | AR098328A1 (pl) |
| AU (1) | AU2014345712B2 (pl) |
| BR (1) | BR112016010271A2 (pl) |
| CA (1) | CA2926893C (pl) |
| ES (1) | ES2728350T3 (pl) |
| HK (1) | HK1222803A1 (pl) |
| IL (1) | IL244960B (pl) |
| MX (1) | MX374290B (pl) |
| MY (1) | MY178726A (pl) |
| NZ (1) | NZ718792A (pl) |
| PH (1) | PH12016500839A1 (pl) |
| PL (1) | PL3066126T3 (pl) |
| RU (1) | RU2727650C2 (pl) |
| TR (1) | TR201907240T4 (pl) |
| TW (1) | TWI524899B (pl) |
| WO (1) | WO2015067586A2 (pl) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ602176A (en) | 2010-03-12 | 2015-01-30 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| ES2948312T3 (es) | 2010-05-31 | 2023-09-08 | Ono Pharmaceutical Co | Derivado de purinona como inhibidor de Btk quinasa |
| CN103958513B (zh) | 2011-11-29 | 2015-12-23 | 小野药品工业株式会社 | 6-羟基嘌呤衍生物盐酸盐 |
| US9416131B2 (en) | 2014-03-25 | 2016-08-16 | Ono Pharmaceutical Co., Ltd. | Prophylactic agent and/or therapeutic agent for diffuse large B-cell lymphoma |
| HRP20200924T8 (hr) * | 2014-09-23 | 2023-07-21 | F. Hoffmann - La Roche Ag | Postupak primjene imunokonjugata anti-cd79b |
| WO2016163531A1 (ja) | 2015-04-09 | 2016-10-13 | 小野薬品工業株式会社 | プリノン誘導体の製造方法 |
| CA2986437A1 (en) | 2015-06-08 | 2016-12-15 | Debiopharm International, S.A. | Anti-cd37 immunoconjugate and anti-cd20 antibody combinations |
| CN113999312A (zh) | 2015-06-24 | 2022-02-01 | 豪夫迈·罗氏有限公司 | 具有定制亲和力的抗转铁蛋白受体抗体 |
| WO2017023584A1 (en) * | 2015-08-03 | 2017-02-09 | Gilead Sciences, Inc. | Combination therapies for treating cancers |
| CN108699144B (zh) | 2015-08-28 | 2022-07-19 | 德彪发姆国际有限公司 | 用于检测cd37的抗体和测定 |
| WO2017059224A2 (en) * | 2015-10-01 | 2017-04-06 | Gilead Sciences, Inc. | Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers |
| WO2017059252A1 (en) * | 2015-10-02 | 2017-04-06 | Gilead Sciences, Inc. | Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| WO2017055542A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
| US11278629B2 (en) | 2016-11-02 | 2022-03-22 | Debiopharm International, S.A. | Methods for improving anti-CD37 immunoconjugate therapy |
| US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018183929A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| WO2019020606A1 (en) * | 2017-07-26 | 2019-01-31 | F. Hoffmann-La Roche Ag | POLYTHERAPY WITH BET INHIBITOR, BCL-2 INHIBITOR AND ANTI-CD20 ANTIBODY |
| CR20200061A (es) | 2017-08-08 | 2020-05-23 | Nanostring Technologies Inc | Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de células b grandes difusas (dlbcl) |
| MX2020012755A (es) | 2018-05-30 | 2021-02-26 | Debiopharm Int Sa | Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37). |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL136544A0 (en) * | 1997-12-05 | 2001-06-14 | Scripps Research Inst | Humanization of murine antibody |
| MXPA05004022A (es) * | 2002-10-17 | 2005-10-05 | Genmab As | Anticuerpos monoclonales humanos contra cd20. |
| US7312243B1 (en) | 2003-08-29 | 2007-12-25 | Jay Pravda | Materials and methods for treatment of gastrointestinal disorders |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| WO2009018411A1 (en) * | 2007-07-31 | 2009-02-05 | Regeneron Pharmaceuticals, Inc. | Human antibodies to human cd20 and method of using thereof |
| ES2948312T3 (es) * | 2010-05-31 | 2023-09-08 | Ono Pharmaceutical Co | Derivado de purinona como inhibidor de Btk quinasa |
| CA3110966A1 (en) * | 2011-10-19 | 2013-04-25 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (btk) |
| US20130302274A1 (en) * | 2011-11-25 | 2013-11-14 | Roche Glycart Ag | Combination therapy |
| CN103958513B (zh) * | 2011-11-29 | 2015-12-23 | 小野药品工业株式会社 | 6-羟基嘌呤衍生物盐酸盐 |
| EP2922827A4 (en) * | 2012-11-20 | 2016-06-08 | Celgene Avilomics Res Inc | METHOD FOR THE TREATMENT OF A DISEASE OR DISEASE RELATED TO BRUTON TYROSINE KINASE |
| DK3003309T3 (da) | 2013-05-30 | 2020-12-14 | Infinity Pharmaceuticals Inc | Behandling af cancer med PI3-kinase-isoform modulatorer |
| EP3076974A1 (en) | 2013-12-05 | 2016-10-12 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| RS63364B1 (sr) | 2014-08-11 | 2022-07-29 | Acerta Pharma Bv | Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora |
-
2014
- 2014-11-04 CA CA2926893A patent/CA2926893C/en active Active
- 2014-11-04 AU AU2014345712A patent/AU2014345712B2/en active Active
- 2014-11-04 RU RU2016122232A patent/RU2727650C2/ru active
- 2014-11-04 US US14/532,247 patent/US20150125446A1/en not_active Abandoned
- 2014-11-04 BR BR112016010271A patent/BR112016010271A2/pt active Search and Examination
- 2014-11-04 ES ES14796468T patent/ES2728350T3/es active Active
- 2014-11-04 KR KR1020167014779A patent/KR101874215B1/ko active Active
- 2014-11-04 CN CN202210119724.2A patent/CN114632158A/zh active Pending
- 2014-11-04 MY MYPI2016701617A patent/MY178726A/en unknown
- 2014-11-04 CN CN201480061326.3A patent/CN105792846A/zh active Pending
- 2014-11-04 EP EP14796468.8A patent/EP3066126B1/en active Active
- 2014-11-04 PL PL14796468T patent/PL3066126T3/pl unknown
- 2014-11-04 JP JP2016524505A patent/JP6478989B2/ja active Active
- 2014-11-04 NZ NZ718792A patent/NZ718792A/en unknown
- 2014-11-04 TR TR2019/07240T patent/TR201907240T4/tr unknown
- 2014-11-04 CN CN202110948035.8A patent/CN113995843A/zh active Pending
- 2014-11-04 MX MX2016005801A patent/MX374290B/es active IP Right Grant
- 2014-11-04 WO PCT/EP2014/073640 patent/WO2015067586A2/en active Application Filing
- 2014-11-06 TW TW103138580A patent/TWI524899B/zh active
- 2014-11-06 AR ARP140104176A patent/AR098328A1/es unknown
-
2016
- 2016-04-06 IL IL244960A patent/IL244960B/en unknown
- 2016-05-05 PH PH12016500839A patent/PH12016500839A1/en unknown
- 2016-09-21 HK HK16111064.0A patent/HK1222803A1/zh unknown
-
2019
- 2019-11-11 US US16/679,483 patent/US12186392B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3066126T3 (pl) | Leczenie skojarzone z zastosowaniem niefukozylowanego przeciwciała anty-CD20 i inhibitora BTK | |
| HK1220206A1 (zh) | 抗體及其用途 | |
| HK1225715A1 (zh) | 氮雜-吡啶酮化合物及其用途 | |
| HK1214135A1 (zh) | 包含 抑制劑和第二抑制劑的組合療法 | |
| ME03090B (me) | Pirazolamidni spoj i njegova upotreba u medicini | |
| CL2016001646A1 (es) | Anticuerpos y fragmentos anti-vista | |
| TWI559931B (en) | Combination therapy with an anti-ang2 antibody and a cd40 agonist | |
| DK3290407T3 (da) | Bromodomæneinhibitorer | |
| KR102524524B9 (ko) | 통합된 폐쇄 장치 구성요소 및 방법 | |
| DK3026062T3 (da) | Anti-pd-1-antistof og anvendelse deraf | |
| DK3043763T3 (da) | Stimulerings- og behandlingsindretning | |
| DK3003039T3 (da) | Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser | |
| DE112014004531A5 (de) | Baugruppe mit Reibeinrichtung | |
| CL2015001049A1 (es) | Terapia de combinación de anticuerpos anti-her3 | |
| EP2988742A4 (en) | THIAZOLES AND USES THEREOF | |
| PL3030519T3 (pl) | Trójpierścieniowe związki benzoksaborolu i ich zastosowania | |
| HK1212958A1 (zh) | 定劑量閥 | |
| DK2969005T3 (da) | Attenuerede influenzavira og -vacciner | |
| DE112014002764A5 (de) | Schuh und Schuhset | |
| EP3049999A4 (en) | PRESENTATION APPARATUS (RECORDING AND DE-REGISTRATION) | |
| EP3051144A4 (en) | COMPRESSORS AND CHARGERS | |
| PL2953868T3 (pl) | Urządzenie uruchamiające i dozujące | |
| BR112015024661A2 (pt) | silo e silo elevado | |
| FR3007291B1 (fr) | Composition cicatrisante et utlisation | |
| FR3010707B1 (fr) | Caisse assemblable et demontable |